Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Reuters+1

15 December 2025

EPA:SAN.PA · NASDAQ:SNY · Pharmaceuticals · Stock Market

#1 STRONG BUY

Kodiak Gas Services

NYSE:KGS • Energy infrastructure 88/100 • ★★★★☆

#2 STRONG BUY

Neurocrine Biosciences

NASDAQ:NBIX • Healthcare 87/100 • ★★★★☆

#3 STRONG BUY

Alphabet Class A

NASDAQ:GOOGL • Communication services 85/100 • ★★★★☆

#4 BUY ON WEAKNESS

Applied Materials

NASDAQ:AMAT • Semiconductor equipment 84/100 • ★★★★☆

#5 ACCUMULATE

JPMorgan Chase

NYSE:JPM • Financials 80/100 • ★★★★☆

View full portfolio

#1

Consumer Confidence • 10:00 ET

A large surprise can reset expectations for household spending and near-term growth, with read-through to Treasuries, USD and cyclical stocks.

#2

New Home Sales • 10:00 ET

Housing remains highly rate-sensitive; the print can move homebuilders, mortgage-sensitive names and the long end of the Treasury curve.

#3

Intuit earnings • After close

Guidance can influence software multiples and sentiment around U.S. small-business activity.

View full calendar